Several GLP-1 Injectables Enter National Basic Medical Insurance List for the First Time, Including Pfizer and Innovent Bio Products, for Treating Adults with Type 2 Diabetes

Deep News12:30

On the morning of November 14, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2026 edition).

Among the inclusions, several GLP-1 injectables have been added to the national basic medical insurance list for the first time.

These include Pfizer (NYSE: PFE)'s enoglutide injection, a biased GLP-1 receptor agonist, indicated for the treatment of adults with type 2 diabetes.

Novo-Nordisk A/S (NYSE: NVO)'s insulin icodec semaglutide injection, the world's first and only once-weekly basal insulin/GLP-1RA combination, is also included.

Additionally, Pegbio's vipegnatide injection, China's independently developed PEGylated long-acting GLP-1 formulation, offers a diversified treatment option for diabetes.

INNOVENT BIO (HKEX: 01801)'s mazdutide injection, the world's first and only approved GCG/GLP-1 dual receptor agonist, is included for type 2 diabetes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment